CCND2 (Cyclin D2)

Moreover, cell treatments attenuated the invasiveness of AML cells through the upregulation of TIMP-2 at the transcriptional level. Therefore, this study supports pharmaceutical interest in citrus waste for cancer management, providing evidence on its antileukemic potential in vitro.

Aberrant expression of Nek2 and Hec1 may contribute to ATL pathogenesis.

The recent approval of the HIF2 inhibitor belzutifan represents a landmark advance, yet both primary and acquired resistance remain major barriers...We also discuss translational opportunities, including HIF2 inhibitor combinations with CDK4/6 inhibitors and anti-VEGF agents, and highlight CCND1/CCND2 as potential biomarkers. Finally, we outline future challenges and perspectives for precision-based, mechanism-driven therapy in ccRCC.

These results indicate that BioGAT-LGG effectively captures biologically validated mechanisms and can enable clinically significant subtype classification and biomarker-guided decision-making. This framework thus lays a scalable foundation for multi-omics integration in oncology, which can be further adopted in other tumour types.

P2, N=124, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Jan 2026 --> Jan 2027

Treatment of SUP-B15 cells with dexamethasone (Dex), Imatinib, or their combination significantly suppressed proliferation and promoted apoptosis, which was accompanied by increases in intracellular ATP, calcium, and glucose. Our findings indicate that P2RX1 may exert this function through modulating energy metabolism and calcium homeostasis, resulting in elevated intracellular calcium levels. Sustained elevation of calcium promotes apoptosis, whereas exogenous ATP activates P2RX1, enhances calcium influx, and attenuates the suppression of apoptosis associated with P2RX1 underexpression, ultimately correlating with improved treatment response.

Translocations occurred in 11 (61.1%) PCL patients; IGH::CCND1 and IGH::MYC were more frequent in PCL compared to MM (22% vs. 14%, p = NS, and 11% vs. 1%, p < 0.05). Druggable aberrations in BRAF, CCND1, PIK3R1, and RAS may be targeted in biomarker-driven therapeutic clinical trials.

This study establishes UBE2M as a critical tumor suppressor in melanoma through the MKK7 neddylation-JNK-EGR1 axis and highlights its potential as a therapeutic target.

Particularly significant are the biomarkers associated with both survival outcomes and recurrence patterns, which may represent key drivers of disease progression. These findings represent an important step toward improved prognostic stratification and therapeutic targeting in IDH wild-type gliomas, addressing a critical unmet need in neuro-oncology.

P2, N=120, Recruiting, Nationwide Children's Hospital | Trial primary completion date: Aug 2028 --> Aug 2029

CCND2, NFASC, ENPP2, EPHA4 and SOX10 were identified to be candidate markers during melanoma progression. The proposed prognostic model had good predictive precision, which may be used for clinical prediction of melanoma development.

In addition to these, an increase in total antioxidant levels was observed. These findings suggest that CHB seems to be a promising anticancer therapeutic agent in the treatment of pancreatic cancer.